Quick Answer
RESMED INC reported R&D Expense of $331.28 million for fiscal year 2025.
RESMED INC R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $331.28M | +7.7% |
| 2024 | $307.52M | +6.9% |
| 2023 | $287.64M | +13.4% |
| 2022 | $253.57M | +12.6% |
| 2021 | $225.28M | +11.6% |
| 2020 | $201.95M | +11.8% |
| 2019 | $180.65M | +16.4% |
| 2018 | $155.15M | +7.4% |
| 2017 | $144.47M | +21.8% |
| 2016 | $118.65M | +3.3% |
| 2015 | $114.86M | -2.8% |
| 2014 | $118.23M | -1.6% |
| 2013 | $120.12M | +9.5% |
| 2012 | $109.73M | +19.3% |
| 2011 | $92.01M | +22.3% |
| 2010 | $75.20M | +19.3% |
| 2009 | $63.06M | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| December 31, 2025 | $90.97M | +11.8% | +4.2% |
| September 30, 2025 | $87.32M | +9.8% | +4.0% |
| March 31, 2025 | $83.94M | +8.9% | +3.2% |
| December 31, 2024 | $81.37M | +10.1% | +2.3% |
| September 30, 2024 | $79.52M | +5.0% | +3.2% |
| March 31, 2024 | $77.07M | +0.8% | +4.3% |
| December 31, 2023 | $73.88M | +5.7% | -2.4% |
| September 30, 2023 | $75.71M | +19.8% | -0.9% |
- RESMED INC showed an increase of +7.7% in R&D Expense compared to the prior fiscal year.
- Over the 2009–2025 period, RESMED INC’s r&d expense has grown by 425.4% (from $63.06 million to $331.28 million).
- The most recent figure is from RESMED INC’s fiscal year 2025 report (Form 10-K), filed with the SEC on August 8, 2025.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: